ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn

Care Award Finalist
Click to Enlarge

ARKAY Pipeline DiagramClick to Enlarge

Why Now Is the Time to Invest, Partner & Collaborate

ARKAY is a privately-held, clinical stage company. Currently, there are no anti-inflammatory 'Beta cell-centric' therapies on the market. This is why the opportunity to capitalize on this cutting-edge medicine is so great.

Our lead combination product, RK-01 was efficacious and safe in the preclinical PoC studies performed using C57BL/6J DIO (Diet-induced obesity) mice with pancreatic beta-cell dysfunction and insulin resistance*.

ARKAY's product concept has been validated by human PoC in controlled clinical studies for using combinations that contain Valsartan or Celecoxib for treating Type 2 diabetes. 

ARKAY Therapeutics has established fully protected intellectual space for advancing anti-inflammatory 'Beta-cell-centric' therapies. U.S. patent US 9,839,644 B2 "Formulations and Methods for Treatment of Metabolic Syndrome” was issued on December 12, 2017. It describes in detail over 60 formulations and methods for treating Type 2 diabetes, prediabetes, and metabolic disease-related disorders. A continuation patent application (Publication Number: US-2018-0042945-A1) has been filed to protect several additional patient-centric formulations and methods. ARKAY's IND application for evaluating the superiority of RK-01 over Metformin in obese type 2 diabetes patients with inadequate glycemic control was approved by the FDA in May 2018 (ClinicalTrials.gov Identifier: NCT03686657).

Gain a more in-depth view of our organization and the kinds of medication we’re creating by clicking here.

*ARKAY has been operating as a virtual company by collaborating with leading CROs

Collaborators

The U.S. FDA designated RK-01 as a "Prototype" drug when it cleared/approved the IND application. ARKAY is collaborating with Albany Medical College, one of the premier medical schools for clinical research, and leading CROs for formulation development, clinical supplies, and clinical trial monitoring and data management. Leading law firms have partnered with ARKAY for intellectual property and corporate governance. 

 Collaborators
Click to Enlarge

Diabetes Statistics
Click to Enlarge

Type 2 Diabetes by the Numbers

Type 2 diabetes is a pandemic and the patient population is expected to double to over 600 million worldwide and over 40 million in the United States by 2040 (IDF, Facts & Figures). The prevalence of Prediabetes is three times that of Type 2 diabetes.  In 2012, 86 million Americans age 20 or older had prediabetes (American Diabetes Association). The global Type 2 Diabetes market will grow from $20.4 billion in 2012 to $58.7 billion in 2025 (FiercePharma). The global market for Metabolic Syndrome is estimated to be $72.4 billion by 2018 (Biovision). 

Understand Our Company

As a savvy investor, we understand that you’re not going to take a risk without knowing every past, present, and future aspect of our biopharmaceutical company. That’s why we invite you to get to know us and gain a sense of our potential.

Upon request, we provide the Executive Summary and the Business Plan that will cover all the information you need to make a smart, well-informed investment decision. Take a moment to read about our founder, president, and CEO, Dr. Ravi Kumar by clicking here.

ARKAY has developed a low-to-moderate risk business plan to develop and commercialize an innovative product that differentiates clinically and mechanistically for a pandemic with enormous market potential in 4 to 5 years with a potential exit strategy in 2 to 3 years.

 Diabetes-Related Complications
Click to Enlarge